Neutrophil-to-Lymphocyte Ratio Predicts Prognosis in Castration-Resistant Prostate Cancer Patients Who Received Cabazitaxel Chemotherapy

Table 3

Distribution of risk classified by risk group.

	Low risk	High risk
Risk factors,	0-1	2-3
Patients, (%)	20 (42.5%)	27 (57.5%)
NLR ≥ 3.83, (%)	2 (10.0%)	18 (66.7%)
Age ≥ 71.4 years, (%)	4 (20.0%)	20 (74.0%)
Lymph node metastasis, (%)	8 (40.0%)	23 (85.2%)